Key Insights

Highlights

Success Rate

83% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

1.2%

1 terminated out of 82 trials

Success Rate

83.3%

-3.2% vs benchmark

Late-Stage Pipeline

4%

3 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed with results

Key Signals

1 with results83% success

Data Visualizations

Phase Distribution

59Total
Not Applicable (11)
Early P 1 (11)
P 1 (27)
P 2 (7)
P 3 (1)
P 4 (2)

Trial Status

Recruiting47
Not Yet Recruiting21
Completed5
Enrolling By Invitation3
Active Not Recruiting2
Terminated1

Trial Success Rate

83.3%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (82)

Showing 20 of 20 trials
NCT06991114Phase 2Recruiting

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

NCT07734012Phase 2Not Yet RecruitingPrimary

Mycophenolate After Stem Cell Transplant for Systemic Sclerosis

NCT07729995Phase 1Not Yet Recruiting

BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease

NCT07732309Phase 1Not Yet Recruiting

A Study of ATG-201 in Adult Participants With Autoimmune Diseases

NCT06655155Phase 2RecruitingPrimary

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

NCT06843239Phase 2Active Not RecruitingPrimary

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

NCT07087912Phase 4Recruiting

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

NCT07402226Not ApplicableRecruitingPrimary

Systemic Sclerosis DIet for GastrointESTinal Symptoms

NCT07277491Completed

Assessment of Nutritional Status in Rheumatic Diseases and Association to Disease Activity

NCT07526350Early Phase 1Recruiting

MTS109 in Patients With Refractory Autoimmune Diseases

NCT07473154Phase 1Recruiting

Controlling Hyperactive Immunity With Long-lived Lymphocytes

NCT07661836Not ApplicableActive Not Recruiting

Personalized Online Occupational Therapy Intervention for Adults With Scleroderma

NCT07641634Phase 1Recruiting

A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.

NCT07650565Not ApplicableNot Yet RecruitingPrimary

Tissue Modeling in Systemic Sclerosis Using Induced Pluripotent Stem Cells (iPSCs)

NCT06708845Phase 1Recruiting

US Zamto-cel Autoimmune Diseases

NCT07642297Not Yet RecruitingPrimary

TL1A Inhibition in Systemic Sclerosis-Related Skin Fibrosis and Immunological Alterations: A Proof-of-Concept In Vitro Study (FIBROSTOP)

NCT05000216Phase 2Terminated

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT07527936Early Phase 1SuspendedPrimary

A Study of BEN301 Injection in theTreatment of Autoimmune Diseases

NCT06308978Phase 1Recruiting

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

NCT07586267Early Phase 1Recruiting

CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease

Scroll to load more

Research Network

Activity Timeline